A metanalysis noted that CAD patients with the highest pentraxin-3 level had an increased risk of all-cause mortality, cardiac death, and cardiac events, but elevated pentraxin-3 level appeared to not significantly increase the risk of cardiac events in the stable CAD subgroup [8]. The gene discussed is PTX3; the disease is coronary artery disorder.